Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From DBV Technologies

Stallergenes Greer Gets Hold Of Nestlé’s Palforzia For Peanuts

Nestlé has finally divested the peanut allergy business acquired in 2019 to much fanfare after the treatment spectacularly failed to live up to its blockbuster potential.

Deals Strategy

Nestlé Ponders Least Painful Exit From Peanut Allergy Misfire

Heralded as a potential blockbuster, Nestlé's acquisition of Palforzia has proved to be a very expensive mistake.

Business Strategies Launches

Finance Watch: Certain Offerings Find Their Way To Investors In Tough Market

Public Company Edition: The stock market has been unkind to biotech firms but investors rewarded some drug developers for clinical trial successes, including Scholar Rock and Day One, which raised $205m and $172.5m, respectively. However, some SPAC deals and an IPO never got off the ground.

Financing Business Strategies

BMS’ Cell Therapy For Lymphoma On Track For EU-Wide Approval

Several new drugs are now on track for an EU marketing authorization after getting the EMA’s thumbs up this week. 

Gene Therapy Approvals
See All

Company Information

  • Industry
  • Medical Devices
  • Pharmaceuticals
    • Vaccines
    • Drug Delivery
      • Macromolecule
      • Transdermal
  • In Vitro Diagnostics
    • Chemistry, Immunoassay
  • Biotechnology
    • Large Molecule
    • Drug Discovery Tools
      • ADMET
UsernamePublicRestriction

Register